Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
iShares USD Corp Bond UCITS ETF Market Cap
Based on ratings from 10 stock analysts, the iShares USD Corp Bond UCITS ETF stock price is expected to increase by 136.69% in 12 months. This is calculated by using the average 12-month stock price forecast for iShares USD Corp Bond UCITS ETF. The lowest target is $17 and the highest is $31. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned LQDA 9 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect iShares USD Corp Bond UCITS ETF to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LQDA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of LQDA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andrew Fein HC Wainwright & Co. | Buy | $29 | Reiterates | Nov 14, 2024 |
| Serge Belanger Needham | Buy | $19 | Reiterates | Nov 14, 2024 |
| Greg Harrison Scotiabank | Sector Outperform | $30 | Initiates | Oct 16, 2024 |
| Cory Jubinville LifeSci Capital | Outperform | $30 | Initiates | Oct 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $29 | Reiterates | Aug 23, 2024 |
| Serge Belanger Needham | Buy | $19 | Reiterates | Aug 22, 2024 |
| Greg Harrison B of A Securities | Buy | $23 | Maintains | Aug 20, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $29 | Maintains | Aug 20, 2024 |
| Julian Harrison BTIG | Buy | $25 | Maintains | Aug 20, 2024 |
| Serge Belanger Needham | Buy | $25 | Reiterates | Aug 19, 2024 |
| Julian Harrison BTIG | Buy | $25 | Maintains | Aug 19, 2024 |
| Ryan Deschner Raymond James | Strong Buy | $27 | Upgrade | Aug 19, 2024 |
| Ryan Deschner Raymond James | Outperform | $27 | Initiates | Aug 16, 2024 |
| Serge Belanger Needham | Buy | $25 | Reiterates | Aug 13, 2024 |
| Serge Belanger Needham | Buy | $25 | Maintains | Aug 8, 2024 |
| Serge Belanger Needham | Buy | $28 | Reiterates | Jul 18, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $32 | Reiterates | Jul 10, 2024 |
| Andreas Argyrides Oppenheimer | Perform | Initiates | Jun 25, 2024 | |
| Serge Belanger Needham | Buy | $28 | Reiterates | Jun 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $32 | Reiterates | May 15, 2024 |
When did it IPO
2018
Staff Count
145
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Roger A. Jeffs Ph.D.
Market Cap
$909.8M
In 2023, LQDA generated $17.5M in revenue, which was a increase of 9.75% from the previous year. This can be seen as a signal that LQDA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Liquidia Technologies (LQDA) has a consensus price target indicating a 126.1% upside potential. Recent earnings estimate revisions suggest possible near-term stock gains.
Why It Matters - The 126.1% upside potential for Liquidia Technologies (LQDA) suggests significant growth, while rising earnings estimates may indicate a short-term price increase, attracting investor interest.
Fri, 15 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Liquidia's Yutrepia, set for potential 2025 launch, shows strong clinical data amid legal disputes with United Therapeutics. Financial challenges remain, but low valuation may attract investors.
Why It Matters - Liquidia's Yutrepia may disrupt the market in 2025, offering growth potential amid legal resolutions and competitive advantages, making it an attractive investment despite current challenges.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Liquidia Corporation (NASDAQ:LQDA) will host its Q3 2024 earnings conference call on November 13, 2024, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters - The earnings call will provide insights into Liquidia Corporation's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Liquidia Corporation received FDA tentative approval for YUTREPIA™ for PAH and PH-ILD and raised $100 million in capital. The U.S. Supreme Court rejected a patent appeal, benefiting three patents.
Why It Matters - Liquidia's FDA approval for YUTREPIA™ opens new revenue streams in the PAH market, while patent victories enhance competitive position and the $100 million capital raise strengthens financial stability.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Liquidia Technologies, Inc. (LQDA) reported a quarterly loss of $0.37 per share, matching the Zacks Consensus Estimate, compared to a loss of $0.24 per share a year earlier.
Why It Matters - Liquidia Technologies reported a larger quarterly loss than the previous year, signaling potential challenges in revenue growth or cost management, which could impact investor confidence and stock performance.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Pomerantz LLP is investigating claims for investors of Liquidia Corporation (NASDAQ:LQDA). Interested parties can contact Danielle Peyton for more information.
Why It Matters - Investigations into Liquidia Corporation may indicate potential legal issues or financial irregularities, which could impact stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
